Clinical Trial Update: Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating liposome-encapsulated daunorubicin-cytarabine in combination with venetoclax for relapsed, refractory, or untreated acute my…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Venclyxto (Venetoclax)
• Vyxeos (CPX-351)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 2 | Status: RECRUITING